Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?

• Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype.
• Androgen receptor (AR) affects regulatory molecules and signaling pathways in TNBC.
• AR targeting emerges as a promising strategy for treating specific TNBC subtypes.

Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype. The absence of expression and/or amplification of estrogen and progesterone receptor as well as ERBB-2 prevent the use of currently available endocrine options and/or ERBB-2-directed drugs and indicates chemotherapy as the main current therapy. TNBC represents approximately 15% of breast cancer cases with high index of heterogeneity. Here, we review the role of androgen receptor in breast carcinogenesis and its association with alterations in the expression pattern and functional roles of regulatory molecules and signal transduction pathways in TNBC. Additionally, based on the so far preclinical and clinical published data, we evaluate the perspectives for using and/or developing androgen receptor targeting strategies for specific TNBC subtypes.